These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 23590837)

  • 1. Preclinical evaluation of a novel ¹¹¹In-labeled bombesin homodimer for improved imaging of GRPR-positive prostate cancer.
    Carlucci G; Ananias HJ; Yu Z; Hoving HD; Helfrich W; Dierckx RA; Liu S; de Jong IJ; Elsinga PH
    Mol Pharm; 2013 May; 10(5):1716-24. PubMed ID: 23590837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual-Modality Imaging of Prostate Cancer with a Fluorescent and Radiogallium-Labeled Gastrin-Releasing Peptide Receptor Antagonist.
    Zhang H; Desai P; Koike Y; Houghton J; Carlin S; Tandon N; Touijer K; Weber WA
    J Nucl Med; 2017 Jan; 58(1):29-35. PubMed ID: 27516447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical pharmacokinetic, biodistribution, imaging and therapeutic efficacy of (177)Lu-Labeled glycated bombesin analogue for gastrin-releasing peptide receptor-positive prostate tumor targeting.
    Lim JC; Cho EH; Kim JJ; Choi SM; Lee SY; Nam SS; Park UJ; Park SH
    Nucl Med Biol; 2015 Mar; 42(3):234-41. PubMed ID: 25498002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of a technetium-99m labeled bombesin homodimer for GRPR imaging in prostate cancer.
    Yu Z; Carlucci G; Ananias HJ; Dierckx RA; Liu S; Helfrich W; Wang F; de Jong IJ; Elsinga PH
    Amino Acids; 2013 Feb; 44(2):543-53. PubMed ID: 22833158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Receptor-binding, biodistribution, dosimetry, and micro-SPECT/CT imaging of 111In-[DTPA(1), Lys(3), Tyr(4)]-bombesin analog in human prostate tumor-bearing mice.
    Ho CL; Chen LC; Lee WC; Chiu SP; Hsu WC; Wu YH; Yeh CH; Stabin MG; Jan ML; Lin WJ; Lee TW; Chang CH
    Cancer Biother Radiopharm; 2009 Aug; 24(4):435-43. PubMed ID: 19694578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization and evaluation of DOTA-conjugated Bombesin/RGD-antagonists for prostate cancer tumor imaging and therapy.
    Stott Reynolds TJ; Schehr R; Liu D; Xu J; Miao Y; Hoffman TJ; Rold TL; Lewis MR; Smith CJ
    Nucl Med Biol; 2015 Feb; 42(2):99-108. PubMed ID: 25459113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts.
    Chen X; Park R; Hou Y; Tohme M; Shahinian AH; Bading JR; Conti PS
    J Nucl Med; 2004 Aug; 45(8):1390-7. PubMed ID: 15299066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. (99m)technetium-HYNIC(tricine/TPPTS)-Aca-bombesin(7-14) as a targeted imaging agent with microSPECT in a PC-3 prostate cancer xenograft model.
    Ananias HJ; Yu Z; Dierckx RA; van der Wiele C; Helfrich W; Wang F; Yan Y; Chen X; de Jong IJ; Elsinga PH
    Mol Pharm; 2011 Aug; 8(4):1165-73. PubMed ID: 21699202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer.
    Zhang X; Cai W; Cao F; Schreibmann E; Wu Y; Wu JC; Xing L; Chen X
    J Nucl Med; 2006 Mar; 47(3):492-501. PubMed ID: 16513619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroPET imaging of a gastrin-releasing peptide receptor-positive tumor in a mouse model of human prostate cancer using a 64Cu-labeled bombesin analogue.
    Rogers BE; Bigott HM; McCarthy DW; Della Manna D; Kim J; Sharp TL; Welch MJ
    Bioconjug Chem; 2003; 14(4):756-63. PubMed ID: 12862428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving radiopeptide pharmacokinetics by adjusting experimental conditions for bombesin receptor-targeted imaging of prostate cancer.
    Schroeder RP; De Blois E; De Ridder CM; Van Weerden WM; Breeman WA; de Jong M
    Q J Nucl Med Mol Imaging; 2012 Oct; 56(5):468-75. PubMed ID: 23069925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative study on DOTA-derivatized bombesin analog labeled with 90Y and 177Lu: in vitro and in vivo evaluation.
    Koumarianou E; Mikołajczak R; Pawlak D; Zikos X; Bouziotis P; Garnuszek P; Karczmarczyk U; Maurin M; Archimandritis SC
    Nucl Med Biol; 2009 Aug; 36(6):591-603. PubMed ID: 19647165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selection of optimal chelator improves the contrast of GRPR imaging using bombesin analogue RM26.
    Mitran B; Varasteh Z; Selvaraju RK; Lindeberg G; Sörensen J; Larhed M; Tolmachev V; Rosenström U; Orlova A
    Int J Oncol; 2016 May; 48(5):2124-34. PubMed ID: 26983776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo evaluation of a 64Cu-labeled polyethylene glycol-bombesin conjugate.
    Rogers BE; Manna DD; Safavy A
    Cancer Biother Radiopharm; 2004 Feb; 19(1):25-34. PubMed ID: 15068608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small-animal PET of tumors with (64)Cu-labeled RGD-bombesin heterodimer.
    Liu Z; Li ZB; Cao Q; Liu S; Wang F; Chen X
    J Nucl Med; 2009 Jul; 50(7):1168-77. PubMed ID: 19525469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new (68)Ga-labeled BBN peptide with a hydrophilic linker for GRPR-targeted tumor imaging.
    Pan D; Xu YP; Yang RH; Wang L; Chen F; Luo S; Yang M; Yan Y
    Amino Acids; 2014 Jun; 46(6):1481-9. PubMed ID: 24633452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative in vitro and in vivo evaluation of two 64Cu-labeled bombesin analogs in a mouse model of human prostate adenocarcinoma.
    Yang YS; Zhang X; Xiong Z; Chen X
    Nucl Med Biol; 2006 Apr; 33(3):371-80. PubMed ID: 16631086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bombesin antagonist-based radioligands for translational nuclear imaging of gastrin-releasing peptide receptor-positive tumors.
    Abiraj K; Mansi R; Tamma ML; Fani M; Forrer F; Nicolas G; Cescato R; Reubi JC; Maecke HR
    J Nucl Med; 2011 Dec; 52(12):1970-8. PubMed ID: 22080443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation and comparison of a new DOTA and DTPA-bombesin agonist in vitro and in vivo in low and high GRPR expressing prostate and breast tumor models.
    Pujatti PB; Foster JM; Finucane C; Hudson CD; Burnet JC; Pasqualoto KFM; Mengatti J; Mather SJ; de Araújo EB; Sosabowski JK
    Appl Radiat Isot; 2015 Feb; 96():91-101. PubMed ID: 25479439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical comparison of Al18F- and 68Ga-labeled gastrin-releasing peptide receptor antagonists for PET imaging of prostate cancer.
    Chatalic KL; Franssen GM; van Weerden WM; McBride WJ; Laverman P; de Blois E; Hajjaj B; Brunel L; Goldenberg DM; Fehrentz JA; Martinez J; Boerman OC; de Jong M
    J Nucl Med; 2014 Dec; 55(12):2050-6. PubMed ID: 25413139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.